For more than 30 years, HPA has partnered with orthopedic and regenerative medicine companies to successfully navigate the complex regulatory and clinical pathways required for FDA approval. From first-in-human studies through pivotal IDE clinical trials and PMA, De Novo and 510(k) submissions, HPA provides the regulatory strategy, clinical expertise, and project leadership needed to efficiently move innovative orthopedic technologies from concept to commercialization.